Cytokines

A case of episodic and refractory arthritis due to a novel variant of NLRP12
Jiajia Wang, Qian Zhang, Lingxiao Xu, Chengyin Lv, Rui Liu, Miaojia Zhang, Wenfeng Tan

Annals of the Rheumatic Diseases Feb 2020, annrheumdis-2020-217023; DOI: 10.1136/annrheumdis-2020-217023
Single-cell RNA-seq analysis identifies meniscus progenitors and reveals the progression of meniscus degeneration
Hao Sun, Xingzhao Wen, Hongyi Li, Peihui Wu, Minghui Gu, Xiaoyi Zhao, Ziji Zhang, Shu Hu, Guping Mao, Ruofan Ma, Weiming Liao, Zhiqi Zhang

Annals of the Rheumatic Diseases Mar 2020, 79 (3) 408-417; DOI: 10.1136/annrheumdis-2019-215926
Type I interferon signature predicts response to JAK inhibition in haploinsufficiency of A20
Daniella Muallem Schwartz, Sarah A Blackstone, Natalia Sampaio-Moura, Sofia Rosenzweig, Aarohan M Burma, Deborah Stone, Patrycja Hoffmann, Anne Jones, Tina Romeo, Karyl S Barron, Meryl A Waldman, Ivona Aksentijevich, Daniel L Kastner, Joshua D Milner, Amanda K Ombrello

Annals of the Rheumatic Diseases Mar 2020, 79 (3) 429-431; DOI: 10.1136/annrheumdis-2019-215918
Response to : ‘Interleukin-4 as a emerging target for IgG4-related disease’ by Akiyama et al
Rachel S Simpson, Jason K Lee

Annals of the Rheumatic Diseases Feb 2020, annrheumdis-2020-216977; DOI: 10.1136/annrheumdis-2020-216977
Response to: ‘Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease’ by Campochiaro et al
Fleur Cohen-Aubart, Neila Benameur, Zahir Amoura, Julien Haroche

Annals of the Rheumatic Diseases Jan 2020, annrheumdis-2019-216755; DOI: 10.1136/annrheumdis-2019-216755
Interleukin-4 as an emerging therapeutic target for IgG4-related disease
Mitsuhiro Akiyama, Yuko Kaneko, Tsutomu Takeuchi

Annals of the Rheumatic Diseases Jan 2020, annrheumdis-2020-216961; DOI: 10.1136/annrheumdis-2020-216961
Response to: ‘Development and initial validation of diagnostic gene signatures for systemic lupus erythematosus’ by Wang et al
Martin Aringer, Karen Costenbader, Thomas Dörner, Sindhu R Johnson

Annals of the Rheumatic Diseases Dec 2019, annrheumdis-2019-216807; DOI: 10.1136/annrheumdis-2019-216807
Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
Jing He, Ruijun Zhang, Miao Shao, Xiaozhen Zhao, Miao Miao, Jiali Chen, Jiajia Liu, Xiaoying Zhang, Xia Zhang, Yuebo Jin, Yu Wang, Shilei Zhang, Lei Zhu, Alexander Jacob, Rulin Jia, Xujie You, Xue Li, Chun Li, Yunshan Zhou, Yue Yang, Hua Ye, Yanying Liu, Yin Su, Nan Shen, Jessy Alexander, Jianping Guo, Julian Ambrus, Xin Lin, Di Yu, Xiaolin Sun, Zhanguo Li

Annals of the Rheumatic Diseases Jan 2020, 79 (1) 141-149; DOI: 10.1136/annrheumdis-2019-215396
Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors
Anja Meyer, Paula S Wittekind, Konstantin Kotschenreuther, Joanna Schiller, Julia von Tresckow, Thomas H Haak, David M Kofler

Annals of the Rheumatic Diseases Nov 2019, annrheumdis-2019-216576; DOI: 10.1136/annrheumdis-2019-216576
Response to: ‘Tocilizumab in patients with adult-onset Still’s disease refractory to glucocorticoid treatment’ by Lee
Yuko Kaneko, Hideto Kameda, Kei Ikeda, Tomonori Ishii, Kosaku Murakami, Hyota Takamatsu, Yoshiya Tanaka, Takayuki Abe, Tsutomu Takeuchi

Annals of the Rheumatic Diseases Dec 2019, 78 (12) e134; DOI: 10.1136/annrheumdis-2018-214653

Main menu

Cytokines

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Cytokines

Pages